Skip to main content
Fig. 6 | Cardiovascular Diabetology

Fig. 6

From: Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention

Fig. 6

Assessment of lifestyle interventions and pharmacotherapies on CVD risk and liver histology features. ACC Acetyl-CoA carboxylase, ACEi angiotensin converting enzyme inhibitor, ARBs angiotensin II receptor blockers, CVD cardiovascular disease, GLP-1RA glucagon-like peptide 1 receptor agonist, NASH non-alcoholic steatohepatitis, PCSK9 proprotein convertase subtilisin/kexin type 9, SGLT-2i sodium-glucose cotransporter 2 inhibitor

Back to article page